Display options
Cite
Végvári Á, Shavkunov AS, Fehniger TE, et al. Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clin Transl Med. 2016;5(1):10doi: 10.1186/s40169-016-0090-9.
Végvári, �. �., Shavkunov, A. S., Fehniger, T. E., Grabau, D., Niméus, E., & Marko-Varga, G. (2016). Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clinical and translational medicine, 5(1), 10. https://doi.org/10.1186/s40169-016-0090-9
Végvári, Ákos, et al. "Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging." Clinical and translational medicine vol. 5,1 (2016): 10. doi: https://doi.org/10.1186/s40169-016-0090-9
Végvári Á, Shavkunov AS, Fehniger TE, Grabau D, Niméus E, Marko-Varga G. Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging. Clin Transl Med. 2016 Mar;5(1):10. doi: 10.1186/s40169-016-0090-9. Epub 2016 Mar 10. PMID: 26965929; PMCID: PMC4786513.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Med. 2016 Mar;5(1):10. doi: 10.1186/s40169-016-0090-9. Epub 2016 Mar 10.

Localization of tamoxifen in human breast cancer tumors by MALDI mass spectrometry imaging.

Clinical and translational medicine

Ákos Végvári, Alexander S Shavkunov, Thomas E Fehniger, Dorthe Grabau, Emma Niméus, György Marko-Varga

Affiliations

  1. Department of Biomedical Engineering, Clinical Protein Science and Imaging, Lund University, BMC D13, 221 84, Lund, Sweden. [email protected].
  2. Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA.
  3. Department of Biomedical Engineering, Clinical Protein Science and Imaging, Lund University, BMC D13, 221 84, Lund, Sweden.
  4. Department of Oncology and Pathology, Clinical Science, Lund University, Lund, Sweden.
  5. Department of Surgery, Skåne University Hospital, Lund, Sweden.

PMID: 26965929 PMCID: PMC4786513 DOI: 10.1186/s40169-016-0090-9

Abstract

BACKGROUND: Tamoxifen is used in endocrine treatment of breast cancer to inhibit estrogen signaling. A set of stratified ER-positive and ER-negative tumor sections was subjected to manual deposition of tamoxifen solution in order to investigate its spatial distribution upon exposure to interaction within thin tissue sections.

METHODS: The localization of tamoxifen in tumor sections was assessed by matrix assisted laser deposition/ionization mass spectrometry imaging. The images of extracted ion maps were analyzed for comparison of signal intensity distributions.

RESULTS: The precursor ion of tamoxifen (m/z 372.233) displayed heterogeneous signal intensity distributions in histological compartments of tumor tissue sections. The levels of tamoxifen in tumor cells compared with stroma were higher in ER-positive tissues, whereas ER-negative tissue sections showed lower signal intensities in tumor cells.

CONCLUSIONS: The experimental model was successfully applied on frozen tumor samples allowing for differentiation between ER groups based on distribution of tamoxifen.

Keywords: Drug localization; Drug quantification; Estrogen receptor stratification; Human breast cancer; MALDI-mass spectrometry imaging; Tamoxifen treatment

References

  1. J Mass Spectrom. 2003 Oct;38(10):1081-92 - PubMed
  2. Mass Spectrom Rev. 2016 Jan-Feb;35(1):147-69 - PubMed
  3. Rapid Commun Mass Spectrom. 2006;20(6):965-72 - PubMed
  4. Anal Bioanal Chem. 2014 Jul;406(19):4601-10 - PubMed
  5. Anal Bioanal Chem. 2015 Mar;407(8):2245-53 - PubMed
  6. Rapid Commun Mass Spectrom. 2011 Feb 28;25(4):503-10 - PubMed
  7. Br J Pharmacol. 2015 Feb;172(4):1148-63 - PubMed
  8. Assay Drug Dev Technol. 2015 Jun;13(5):277-84 - PubMed
  9. Lab Invest. 2015 Apr;95(4):422-31 - PubMed
  10. Anal Chem. 1997 Dec 1;69(23):4751-60 - PubMed
  11. J Proteome Res. 2015 Jul 2;14(7):2807-18 - PubMed
  12. Int J Oncol. 2015 Mar;46(3):893-906 - PubMed
  13. Elife. 2016 Feb 02;5: - PubMed
  14. Adv Drug Deliv Rev. 2013 Jul;65(8):1074-85 - PubMed
  15. Drug Metab Dispos. 2014 Mar;42(3):441-7 - PubMed
  16. J Proteomics. 2011 Jun 10;74(7):982-92 - PubMed
  17. Rapid Commun Mass Spectrom. 2012 Jul 15;26(13):1549-56 - PubMed
  18. Anal Bioanal Chem. 2015 Mar;407(8):2107-16 - PubMed
  19. Sci Rep. 2013 Oct 04;3:2859 - PubMed
  20. PLoS One. 2010 Jul 14;5(7):e11411 - PubMed
  21. J Histochem Cytochem. 2015 Oct;63(10 ):762-71 - PubMed
  22. J Proteomics. 2012 Aug 30;75(16):4999-5013 - PubMed
  23. Anal Chem. 2011 Nov 1;83(21):8329-36 - PubMed
  24. Biomark Med. 2015;9(9):869-76 - PubMed
  25. Life Sci. 1986 Dec 1;39(22):2037-48 - PubMed
  26. Anal Chem. 2014 Aug 19;86(16):8473-80 - PubMed
  27. Clin Proteomics. 2015 May 12;12(1):13 - PubMed
  28. J Proteome Res. 2013 Dec 6;12(12):5626-33 - PubMed

Publication Types